As the biggest threat to human health, cancer has occupied most of the energy of scientists in recent years, and effective evaluation of the efficacy of anticancer drugs is an important part of the successful development of anticancer drugs. In this regard, more and more in vitro and in vivo models have been used to assess the effects of drugs, and patient derived organoid is undoubtedly the most promising model. With more than a decade of experience in drug development, Creative Biolabs has established an advanced patient derived organoid platform that not only has a comprehensive library of patient derived organoids, but also provides you with a wide range of drug evaluation services based on this.
Cancer cell lines and patient-derived xenograft (PDX) are commonly used preclinical models for screening anticancer drugs and evaluating drug responses. Cancer cell lines have the characteristics of rapid proliferation, and thus become a powerful tool for high-throughput screening of drugs. However, compared with actual tumors, histological and genetic characteristics have changed significantly, therefore, drugs that perform well on tumor cell lines do not perform well in clinical trials. The PDX model prepared by subcutaneous or orthotopic transplantation of a patient's fresh tumor tissue into an immunodeficient mouse is able to better mimic the biological characteristics of a native tumor compared to a tumor cell line, but its expensive price and the consumption of time and resources limit its application in drug development. Tumor organoid can be considered to be high-quality drug screening and evaluation models. In addition to the use of pluripotent stem cells or organ progenitor cells, tissue-derived tumors from patients can also be established as a model of organoids, namely patient derived organoid (PDO). More than 12 PDO models have been developed so far. Phenotypic and genotypic analysis showed that PDOs are similar in characteristics to natural tumors and possess the same gene mutation profile, and their accuracy in predicting drug reactivity and non-reactivity is 88% and 100%. Morphologically, PDO is also similar to primary tumors; and immunohistological markers used to diagnose tumors can also be expressed in the same pattern in PDOs.
Therefore, individual PDOs have the same histological and genetic characteristics as the corresponding patients, so that each PDO can be tested as a small patient trial. In addition, the short production cycle of PDO ensures a good supply during drug evaluation and allows patients to obtain individualized treatments that are more suitable for them.
Fig.1 Applications of patient-derived organoids (PDOs).
PDO is an ideal and promising model for individualized cancer treatment and anticancer drug development. Creative Biolabs is a CRO company with excellent drug development experience. We have established a library of in-vivo and in vitro models for drug screening and evaluation, and are always being well prepared to provide comprehensive drug evaluation services based on this.
For Research Use Only.
